Apheresis Therapy for Steroid-Resistant Idiopathic Nephrotic Syndrome: Report on a Case Series. (9th October 2019)

• Record Type: Journal Article
• Authors: Naciri Bennani, Hamza; Jouve, Thomas; Noble, Johan; Rostaing, Lionel; Malvezzi, Paolo; Tetaz, Rachel
• Other Names: Fujigaki Yoshihide Academic Editor.
• Is Part Of: Case reports in nephrology. Volume 2019(2019)
• Publication Date: 2019-10-09
• Subjects: Nephrology -- Periodicals; Kidneys -- Diseases -- Periodicals; Nephrology; Kidneys -- Diseases; Nephrology; Periodicals; Electronic journals; Periodicals; 616.61
• DOI: 10.1155/2019/7304786
• Languages: English
• ISSNs: 2090-6641

Abstract

Abstract : Idiopathic nephrotic syndrome (INS) represents 15%–30% of adulthood glomerulopathies. Corticosteroids have been the main treatment for decades and are effective in 70% of minimal-change disease patients and ~30% of focal segmental glomerulosclerosis patients. Multidrug-resistant (steroids, calcineurin-inhibitors, cyclophosphamide, mycophenolate-mofetil, rituximab) idiopathic nephrotic syndrome is a major therapeutic challenge in nephrology. Apheresis (double-filtration plasmapheresis or semi specific immunoadsorption) could act by eliminating the circulating factor (apolipoproteinA1b, solubleCD40L, suPAR) increasing glomerular permeability seen in INS. The aim of the study was to report the outcome of three patients with multidrug-resistant INS treated successfully with apheresis.